Olema Pharmaceuticals (OLMA) Expected to Announce Earnings on Monday

Olema Pharmaceuticals (NASDAQ:OLMA) is anticipated to release its Q3 2026 resultson Monday, November 9th. Analysts expect Olema Pharmaceuticals to post earnings of ($0.60) per share and revenue of $1.25 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06). On average, analysts expect Olema Pharmaceuticals to post ($2.43) EPS for the current fiscal year and ($2.72) EPS for the next fiscal year.

Olema Pharmaceuticals Stock Performance

NASDAQ OLMA opened at $7.00 on Monday. The company’s 50 day simple moving average is $8.84 and its two-hundred day simple moving average is $14.17. The stock has a market capitalization of $612.50 million, a PE ratio of -3.30 and a beta of 2.12. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.86 and a quick ratio of 8.86. Olema Pharmaceuticals has a 1 year low of $6.24 and a 1 year high of $36.26.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on OLMA. Weiss Ratings raised shares of Olema Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. HC Wainwright lowered their price target on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Stifel Nicolaus cut their price objective on Olema Pharmaceuticals from $48.00 to $30.00 and set a “buy” rating for the company in a report on Monday, September 14th. JPMorgan Chase & Co. lowered their price target on shares of Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, August 13th. Finally, Citigroup cut their price target on shares of Olema Pharmaceuticals to $59.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $40.60.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for women’s cancers, with an emphasis on hormone receptor-positive breast cancer. The company’s research is centered on treatments designed to address cancer biology and resistance mechanisms that can limit the effectiveness of existing endocrine therapies.

Olema’s lead product candidate is palazestrant, an oral selective estrogen receptor degrader (SERD) being developed for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.